Linden Advisors’s Starling Oncology, Inc. Warrant STLNW Stock Holding History
Bought
Maintained
Sold
Other funds holding STLNW
DM
UOC
RCM
DKCM
KC
QGA
GCL
Linden Advisors's STLNW Position: Q2 2021 in Review
Linden Advisors sold out of Starling Oncology, Inc. Warrant (STLNW) in Q2 2021, closing a stake of 24,316 shares — an estimated $35K sold.
Linden Advisors first reported a position in STLNW in Q2 2020 and held it in 4 quarters. The position peaked at $53K in Q3 2020. 26 funds tracked by Wall St. Rank hold STLNW as of Q2 2021.
- Linden Advisors reported no remaining Starling Oncology, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
- Linden Advisors sold 24,316 Starling Oncology, Inc. Warrant shares in Q2 2021, an estimated $35K.
- Linden Advisors first reported a position in Starling Oncology, Inc. Warrant in Q2 2020 and held it in 4 quarters.
- Linden Advisors's Starling Oncology, Inc. Warrant position peaked at $53K in Q3 2020.
- 26 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q2 2021.
Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.